Eli Lilly releases new data on weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Amycretin has some intriguing results in obesity
Amycretin, an experimental Novo Nordisk obesity pill that targets both amylin and GLP-1 receptors, spurred significant weight loss in a Phase 1 study, the company announced yesterday. Over three months, a daily dose resulted in 10.4% loss in weight; those who took two pills lost 13.1% of their body weight. By comparison, the people taking placebo experienced only 1.1% weight loss. Animal studies suggest that targeting amylin could mean less nausea and muscle loss than GLP-1, but that has yet to be proven in clinical trials.
Read Original Article: Eli Lilly releases new data on weekly insulin »
